Investing14d
JMP Securities reiterates Uber stock Market Perform rating
On Friday, JMP Securities maintained a Market Perform rating on Uber Inc. (NYSE:UBER) without altering its price target. According to the firm, Uber's last closing price of $66.77 reflects a valuation ...
Investing14d
JMP Securities starts Astria Therapeutics stock at Market Outperform
On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49, ...
Investing14d
Mortgage REITs struggle as interest rates rise, says JMP Securities
On Friday, JMP Securities released a comprehensive fourth-quarter earnings preview for the Commercial Mortgage REIT and Commercial Real Estate Finance sector. The report, which covers 22 of the 24 ...
Investing14d
JMP Securities reiterates Uber stock Market Perform rating
On Friday, JMP Securities maintained a Market Perform rating on Uber Inc. (NYSE:UBER) without altering its price target. According to the firm, Uber's last closing price of $66.77 reflects a ...
Investing14d
LegalZoom stock holds Market Outperform rating at JMP Securities
On Friday, JMP Securities maintained its Market Outperform rating on LegalZoom.com Inc (NASDAQ:LZ), reflecting confidence in the company's leading position in the business formations sector.
Investing14d
JMP Securities starts Astria Therapeutics stock at Market Outperform
On Friday, JMP Securities initiated coverage on Astria Therapeutics (NASDAQ: ATXS), assigning a Market Outperform rating and setting a price target of $26.00. The stock, currently trading at $7.49 ...
Business Insider14d
Pharvaris price target raised to $55 from $46 at JMP Securities
JMP Securities analyst Jonathan Wolleben raised the firm’s price target on Pharvaris (PHVS) to $55 from $46 and keeps an Outperform rating on the shares. Pharvaris is the only company with an ...
Business Insider14d
KalVista initiated with an Outperform at JMP Securities
JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a small-molecule plasma kallikrein inhibitor, which could ...
Business Insider14d
Astria Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Jonathan Wolleben initiated coverage of Astria Therapeutics (ATXS) with an Outperform rating and $26 price target Astria is using its half-life extension technology to ...
Business Insider14d
Pharvaris (PHVS) Gets a Buy from JMP Securities
In a report released today, Jonathan Wolleben from JMP Securities maintained a Buy rating on Pharvaris (PHVS – Research Report), with a price target of $55.00. The company’s shares closed ...
Business Insider14d
JMP Securities Sticks to Their Hold Rating for Atlassian (TEAM)
In a report released today, Patrick Walravens from JMP Securities maintained a Hold rating on Atlassian (TEAM – Research Report). The company’s shares closed yesterday at $266.95. Walravens ...